Tilray Will Quintuple Its Medical Marijuana Production In Germany With New Cultivation License
Tilray Brands, Inc. (NASDAQ:TLRY) (TSX:TLRY) announced on Monday that its Germany cannabis cultivation facility, Aphria RX GmbH, has obtained the first new cannabis cultivation license issued under MedCanG, Germany’s new Cannabis Act.
Why It Matters
The new cannabis cultivation license allows Aphria RX to cultivate and manufacture a broad commercial range of medical cannabis, providing patients with better access to high-quality medical cannabis produced in Germany.
Denise Faltischek, the company’s chief strategy officer and head of international, explained that the license allows Tilray to expand the range of treatment options available to patients. “We appreciate the trust that the German Government has placed in Tilray, and we are proud of our team for their groundbreaking work in medical cannabis cultivation and patient care,” Faltischek said.